Pharmaceutical Trends in Sub Saharan Africa

Transcription

1 Pharmaceutical Trends in Sub Saharan Africa Randall Crisp Life Sciences Reginal Manager, Sub Saharan Africa 27 March 2018

2 2 SSA As A Majr Pharmaceutical Market The pharmaceuticals market in Africa is expected t reach a business pprtunity f $45 billin in 2020, prpelled by a cnvergence f changing ecnmic prfiles, rapid urbanizatin, increased healthcare spending and investment, and increasing incidence f chrnic lifestyle diseases. The trpical climate f Africa makes the cntinent the largest reservir f infectius diseases, particularly malaria, (TB), and acquired immune deficiency syndrme (AIDS). With the increasing adptin f Western lifestyle in Africa, there has been a paradigm shift in the burden f illness twards nncmmunicable diseases (NCDs), driving the demand fr chrnic prescriptin drugs. Despite all f this, high grwth within this market is achievable. Rank Cuntry Market ($MM) Rank Cuntry Market ($MM) 1 USA 339,694 2 Japan 94,025 3 China 86,774 4 Germany 45,828 5 France 37,156 6 Brazil 30,670 7 Italy 27,930 8 UK 24,513 9 Canada 21, Spain 20,741

3 3 Sub-Saharan Africa Gegraphically cmprising f 48 cuntries, Sub Saharan Africa (SSA) represents the mst genetically diverse regin. SSA accunts fr 64% f the glbal disease burden frm human immundeficiency virus (HIV/AIDS), tuberculsis (TB) and malaria, but nly 4% f the wrld s health wrkfrce. Its pharmaceuticals sectr faces challenges with high drug prices and regulatins, which pen up pprtunities fr illicit imprts and prductin. Between 2005 and 2015, six f the wrld s 10 fastest-grwing cuntries were in SSA Angla, Nigeria, Ethipia, Chad, Mzambique and Rwanda. In eight f the past 10 years, SSA has grwn faster than Asia. In 2020, the Internatinal Mnetary Fund expects Africa t grw at a rate f 6% - abut the same as Asia. Cntinuing such trends, it is estimated that by 2035, Africa s wrkfrce, which is larger than any ther cntinent, will be making significant strides in the fields f agriculture, healthcare, manufacturing, hspitality and technlgy.

4 4 Cncerns with Running Clinical Trials in SSA In SSA csts, cmplexity, legal requirements and number f amendments assciated with clinical trials are rising cnstantly, which negatively affects the efficient cnduct f trials. This situatin is exacerbated by capacity and funding limitatins, which further increase the wrklad f clinical wrkers. One study fund varius internal factrs assciated with slwing dwn clinical trials; these were summarised int tw brad themes, planning and site rganisatin. Planning factrs related t budget feasibility, clear prject ideas, realistic deadlines, understanding f trial prcesses, adaptatin t the lcal cntext and invlvement f site staff in planning. Site rganisatin factrs cvered staff turnver, emplyment cnditins, career paths, wrklad, delegatin and management. PLS ONE 12(3): e

5 Tp 12 Drugs t Watch in

6 6 What technlgy areas are being prtected in Suth Africa? Chemistry & Metallurgy 27% Medical Science 14% Textile 2% Cnstructin & Mining Suth Africa Technlgy Fcus Machinery 11% 4% Transprtatin Systems 4% Miscellaneus 5% Industrial Manufacturing 11% Electrnics & Telecmmunicatin 7% Agriculture & Fd 7% Digital Cmputing 8% Patent filing standpint: Chemistry & Metallurgy accunts fr 27% f patents filed in Suth Africa. This is clsely fllwed by Medical Science, Machinery & Manufacturing. While public health remains t be a key fcus in Suth Africa, Industry 4.0 is gaining additinal imprtance. Industrie 4.0 will create a shift frm mass prductin t custmized and creative slutins. Innvatin and creativity will be key. Emphasis n educatin all the mre necessary, says Massim De Luca, Head f Trade and Ecnmics at the delegatin f the EU t SA. Des Suth Africa have the right input and utput fr knwledge Wh are prtecting innvatin here? Where are the gaps? Hw can we accelerate thse areas t imprve verall knwledge utput (e.g. IP)?

7 Btswana : Web f Science publicatins where is the innvatin ptential? 7 Innvatin indicatrs Accrding t this study, Six ut f every ten Suth Africans interviewed (base f 1000) claim that they are innvatrs. 20% feel that they are nt reliant n thers t cme up with creative slutins t challenges. Almst half (46%) feel that their idea will be the next big thing in their industry. Radblcks t innvatin & deturs arund issues Capital, r rather lack theref, since 57% f respndents see lack f mney as a barrier t innvatin. Apprximately 29% f respndents see lack f infrastructure t implement a slutin as a barrier. 16% stated that there is a perceived lack f financial reward r benefit t generating innvative ideas. Surce:

8 Trial Starts 8 Clinical Trial Starts by Cuntry :

9 Number f Trials 9 Clinical Trial Starts SSA and MENA : Start Year

10 Number f Trials 10 Clinical Trial Starts by Organizatin SSA and MENA : Start Year

11 Percent f Trials 11 Clinical Trial Starts in Sub Saharan Regins by Organizatin : Start Year

12 Number Of Trials 12 SSA: Trials Over Last 10 Years Start Year Surce: Clarivate Analytics, Crtellis Clinical Trials Intelligence

13 Number Of Trials 13 SSA: Trials Over Last 10 Years By Phase Start Year Surce: Clarivate Analytics, Crtellis Clinical Trials Intelligence

14 Percentage Of Trials 14 SSA: Trials Over Last 10 Years By Spnsr Type Start Year Surce: Clarivate Analytics, Crtellis Clinical Trials Intelligence

15 Percentage Of Trials 15 Suth Africa: Trials Over Last 10 Years By Spnsr Type Start Year Surce: Clarivate Analytics, Crtellis Clinical Trials Intelligence

16 Percentage Of Trials 16 SSA: Trials Last 10 Years: Cmmercially Relevant Cmmercially Relevant Trials are thse trials where the spnsr is recgnized as the drug wner Start Year Surce: Clarivate Analytics, Crtellis Clinical Trials Intelligence

17 Percentage Of Trials 17 Suth Africa: Trials Last 10 Years: Cmmercially Relevant Cmmercially Relevant Trials are thse trials where the spnsr is recgnized as the drug wner Start Year Surce: Clarivate Analytics, Crtellis Clinical Trials Intelligence

18 Percentage Of Trials 18 SSA: Trials Over Last 10 Years: Infectius Disease A trial tagged as infectius disease invlves the testing f a cmpund designed t treat at least ne infectius disease indicatin. It may als be under study in the same trial against a nninfectius disease indicatin. Start Year Surce: Clarivate Analytics, Crtellis Clinical Trials Intelligence

19 Spnsr 19 Tp Spnsrs fr Clinical Trial Starts SSA : Number f Trials

20 20 Tp Academic Spnsrs fr Clinical Trial Starts by Year SSA : Percent f Trial Starts

21 21 Tp Cllabratrs fr Clinical Trial Starts SSA : Number f Trials

22 22 Tp 5 Indicatins fr Clinical Trial Starts fr SSA : Number f Trials

23 Index f Prductivity and Innvatin 23

24 Randall Crisp, clarivate.cm